ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.909,14
-0,25%
S&P 500
5.918,25
-0,88%
Dow Jones
42.659,62
-0,77%
Euro vs US Dollar
1,04035
-0,24%
Bitcoin
94.258,11
0,80%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Cardiff Oncology Inc (CRDF) Börsenkurse

Cardiff Oncology Inc

Cardiff Oncology Inc (CRDF)

NASDAQ
4,27
-0,05
( -1,16% )
Aktualisiert: 21:28:02
Verzögert um 15 Minuten

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
4,27
Gebot
4,26
Fragen
4,27
Volumen
698.869
4,14 Tagesbereich 4,5208
1,44 52-Wochen-Bereich 6,42
Marktkapitalisierung
218,341M
Handelsende
4,32
Handelsbeginn
4,30
Letzte Trade
10
@
4.265
Letzter Handelszeitpunkt
21:28:25
Finanzvolumen
US$ 2.975.470
VWAP
4,2576
Durchschnittliches Volumen (3 Mio.)
2.050.249
Ausgegebene Aktien
51.133.747
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-1,47
Gewinn pro Aktie (EPS)
-0,81
Erlöse
488k
Nettogewinn
-41,47M

Über Cardiff Oncology Inc

Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias. Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

Sektor
Biological Pds,ex Diagnstics
Branche
Biological Pds,ex Diagnstics
Website
cardiffoncology.com
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Cardiff Oncology Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CRDF. The last closing price for Cardiff Oncology was US$4,32. Over the last year, Cardiff Oncology shares have traded in a share price range of US$ 1,44 to US$ 6,42.

Cardiff Oncology currently has 51.133.747 shares in issue. The market capitalisation of Cardiff Oncology is US$220,90 million. Cardiff Oncology has a price to earnings ratio (PE ratio) of -1.47.

CRDF Neueste Nachrichten

Weitere Nachrichten

Form 4 - Statement of changes in beneficial ownership of securities

18 Dezember 2024
Edgar (US Regulatory)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

17 Dezember 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

16 Dezember 2024
Edgar (US Regulatory)

Form 8-K - Current report

10 Dezember 2024
Edgar (US Regulatory)

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (“Cardiff Oncology” or the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to...

10 Dezember 2024
GlobeNewswire Inc.

Form 8-K - Current report

10 Dezember 2024
Edgar (US Regulatory)

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

- Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the...

10 Dezember 2024
GlobeNewswire Inc.

Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC

- Protects the use of onvansertib in combination with standard of care in the KRAS mutated mCRC setting through 2043 - SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc...

19 November 2024
GlobeNewswire Inc.

Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update

- Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the peer-reviewed Journal of Clinical Oncology - - Initial data...

07 November 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 November 2024
Edgar (US Regulatory)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.12-2.733485193624.394.543.8210933364.15749988CS
41.6562.97709923662.625.63952.2645771373.88910495CS
121.6261.13207547172.655.63952.2620502493.64830596CS
262.0693.21266968332.215.63952.0112069943.38268254CS
522.79188.5135135141.486.421.4411923973.53406781CS
156-1.6-27.25724020445.877.320.947709452.87527819CS
2602.98231.0077519381.2925.50.7019038605.83930997CS

CRDF - Frequently Asked Questions (FAQ)

What is the current Cardiff Oncology share price?
The current share price of Cardiff Oncology is US$ 4,27
How many Cardiff Oncology shares are in issue?
Cardiff Oncology has 51.133.747 shares in issue
What is the market cap of Cardiff Oncology?
The market capitalisation of Cardiff Oncology is USD 220,9M
What is the 1 year trading range for Cardiff Oncology share price?
Cardiff Oncology has traded in the range of US$ 1,44 to US$ 6,42 during the past year
What is the PE ratio of Cardiff Oncology?
The price to earnings ratio of Cardiff Oncology is -1,47
What is the cash to sales ratio of Cardiff Oncology?
The cash to sales ratio of Cardiff Oncology is 125,26
What is the reporting currency for Cardiff Oncology?
Cardiff Oncology reports financial results in USD
What is the latest annual turnover for Cardiff Oncology?
The latest annual turnover of Cardiff Oncology is USD 488k
What is the latest annual profit for Cardiff Oncology?
The latest annual profit of Cardiff Oncology is USD -41,47M
What is the registered address of Cardiff Oncology?
The registered address for Cardiff Oncology is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Cardiff Oncology website address?
The website address for Cardiff Oncology is cardiffoncology.com
Which industry sector does Cardiff Oncology operate in?
Cardiff Oncology operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
NXUNXU Inc
US$ 1,5471
(535,62%)
551,38M
WATTEnergous Corporation
US$ 1,775
(331,66%)
193,42M
HOLOMicroCloud Hologram Inc
US$ 6,47
(169,58%)
201,68M
INTZIntrusion Inc
US$ 5,4798
(153,69%)
128,83M
SMXSMX Security Matters Public Company
US$ 0,77
(117,76%)
346,3M
ICGIntchains Group Ltd
US$ 3,76
(-59,70%)
1,21M
ABPAbpro Holdings Inc
US$ 2,12
(-52,78%)
1,95M
LITMSnow Lake Resources Ltd
US$ 0,9603
(-39,98%)
63,89M
TRAWTraws Pharma Inc
US$ 8,18
(-39,05%)
1,1M
LNKSLinkers Industries Ltd
US$ 1,8606
(-31,85%)
874,2k
NXUNXU Inc
US$ 1,5471
(535,62%)
548M
SMXSMX Security Matters Public Company
US$ 0,77
(117,76%)
345,68M
VINCVincerx Inc
US$ 0,3205
(65,21%)
326,81M
XTIAXTI Aerospace Inc
US$ 0,039951
(1,14%)
237,35M
HOLOMicroCloud Hologram Inc
US$ 6,47
(169,58%)
199,6M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
CRDF
Cardiff Oncology
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten